Definitive Healthcare Reports Declining Revenue, Lower 2026 Guidance, and $196M Goodwill Impairment
Summary
Definitive Healthcare reported a year-over-year decline in Q4 and full year 2025 revenue and adjusted profits, issued lower guidance for 2026, and recorded a $196.1 million goodwill impairment charge.
Key Events
-
Revenue Decline Reported
Fourth quarter 2025 revenue decreased 1% to $61.5 million, and full year 2025 revenue fell to $241.5 million from $252.2 million in 2024.
-
Significant Goodwill Impairment
The company recorded a goodwill impairment charge of $19.5 million in Q4 2025 and $196.1 million for the full year 2025, indicating a substantial write-down of asset value.
-
Adjusted Profitability Decreased
Adjusted Net Income for Q4 2025 was $8.6 million, down from $12.6 million in Q4 2024. Full year 2025 Adjusted Net Income was $34.9 million, down from $55.1 million in 2024.
-
Lower Full Year 2026 Guidance
Definitive Healthcare projects full year 2026 revenue in the range of $220.0 – $226.0 million, a further decline from 2025, and Adjusted Net Income Per Diluted Share of $0.14 to $0.17.
Analysis
Definitive Healthcare Corp. reported a significant decline in its financial performance for both the fourth quarter and full fiscal year 2025, with revenue, adjusted net income, and adjusted EBITDA all decreasing year-over-year. The company also provided a weak outlook for full year 2026, projecting further revenue contraction and lower adjusted net income per diluted share compared to 2025. Critically, the company recorded a substantial goodwill impairment charge of $196.1 million for the full year 2025, following an even larger impairment in 2024. This impairment, which is nearly equivalent to the company's current market capitalization, indicates a severe deterioration in the value of its acquired assets and reflects sustained decreases in its stock price. The combination of declining operational results, negative forward guidance, and massive asset write-downs signals significant challenges for the company, especially as its stock trades near 52-week lows.
At the time of this filing, DH was trading at $1.31 on NASDAQ in the Technology sector, with a market capitalization of approximately $198.3M. The 52-week trading range was $1.36 to $5.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.